Initiate at Strong Buy with a $973.89 price target. The elimination of Sanofi development deductions, robust Dupixent growth, and a fortress balance sheet holding $143 per share in net cash create compelling asymmetry against patent cliff worries.
Key points
- $15.1 billion in net cash and marketable securities provides a $143 per share liquidity cushion, anchoring 19% of market capitalization.
- $1.0 billion annual pretax cash flow windfall begins immediately following full repayment of the Sanofi development balance on June 30, 2026.
- $72.14 in projected 2027 non-GAAP earnings per share leaves the stock trading at just 10.2 times earnings, an unwarranted discount.
The call
The market prices Regeneron at 10.2 times 2027 non-GAAP earnings, assuming biosimilar erosion on standard Eylea and post-patent stagnation will permanently impair cash generation. This implies a 15% terminal earnings contraction and ignores $15.1 billion in net liquidity. The current price treats commercial immunology growth as insufficient to offset branded ophthalmology patent expiries.
Quarterly revenue expansion and forecast ($ billions)- Reported revenue ($B)
- Analyst forecast ($B)
Source: Company filings (Q3 2024–Q2 2026) and analyst estimates (Q3 2026E–Q4 2027E) as of October 8, 2026.
We believe the market is far too pessimistic about earnings durability and cash conversion. Dupixent volume expansion across newly approved chronic obstructive pulmonary disease and pediatric indications, combined with the zeroing out of quarterly Sanofi reimbursement deductions, drives 2027 revenue to $19.9 billion. Operating leverage and steady share repurchases support accelerated earnings growth.
Bridge from current share price to twelve-month target ($ per share)Source: Regeneron Q2 2026 balance sheet and 2027 analyst earnings forecast as of October 8, 2026.
Valuation
| Valuation driver | 2027 estimate |
|---|
| Total consolidated revenue | $19.89 billion |
| Non-GAAP operating income | $8.28 billion |
| Non-GAAP net income | $7.50 billion |
| Diluted share count | 104.0 million |
| 2027 non-GAAP earnings per share | $72.14 |
| Target price-to-earnings multiple | 13.5 times |
| Twelve-month price target | $973.89 |
Our $973.89 price target applies a conservative 13.5 times multiple to 2027 non-GAAP earnings of $72.14 per share, well below large-cap biopharma averages. Backing out $143 per share in net cash yields an ex-cash multiple under 12 times. This asymmetric 31.8% upside supports our Strong Buy rating.
Risks
- Accelerated Eylea HD competitive erosion from compounding pharmacies, rival anti-VEGF agents, or regulatory delays on the prefilled syringe.
- Slower international Dupixent penetration or aggressive payer tiering that squeezes realized commercial collaboration profit margins.
- Clinical pipeline setbacks in high-spend Phase 3 oncology or cardiometabolic trials that trigger acquired in-process research write-downs.
What would change my mind
A sustained loss of Dupixent prescription market share in newly launched pulmonary indications accompanied by a rapid collapse of innovative retinal market share below 45%.